Carisma to be added to Russell 2000, Russell 3000, and Russell Microcap

Carisma Therapeutics announced that the Company will join the Russell 2000, Russell 3000 and Russell Microcap Indexes following the conclusion of the 2023 Russell indexes annual reconstitution, effective upon the U.S. markets open today, June 26, 2023. “We are thrilled to be added to the Russell indexes, which marks another notable milestone following the successful closing of our merger in March,” said Steven Kelly, President and Chief Executive Officer of Carisma. “As we continue to advance our pipeline of CAR-Macrophage therapies, we anticipate our inclusion will bring greater market awareness to our CAR-M platform and its potential to overcome the hurdles of current cell therapy in the treatment of solid tumors by modulating the tumor microenvironment through using innate immune system cells. We’re also looking forward to broadening our visibility within the investment community, which we expect will expand our shareholder base and help enhance the liquidity in our stock.”